Diabetes is a chronic metabolic condition affecting an estimated 537 million adults worldwide, and its prevalence continues to rise. While most discussions focus on glycemic control and cardiovascular complications, a growing body of evidence highlights a significant yet often overlooked consequence: impaired bone health and elevated fracture risk. The relationship between diabetes and bone is complex, involving multiple pathophysiological pathways that compromise skeletal integrity. For individuals living with diabetes, understanding these mechanisms is essential for preventing fractures that can severely diminish mobility, independence, and overall quality of life.

How Diabetes Affects Bone Health

Diabetes exerts a detrimental influence on bone through several interconnected mechanisms that alter both the structure and material properties of the skeleton. Chronic hyperglycemia, insulin deficiency or resistance, and systemic inflammation all contribute to a bone that is weaker and more susceptible to fracture. Researchers have identified specific cellular and molecular changes that help explain why diabetic bone is often more fragile than would be predicted by standard bone density measurements.

The Role of Advanced Glycation End Products (AGEs)

One of the most important mechanisms linking diabetes to poor bone quality involves the accumulation of advanced glycation end products (AGEs). When blood sugar levels remain persistently high, glucose molecules non-enzymatically bind to proteins, lipids, and nucleic acids, forming AGEs that accumulate in tissues over time. In bone, AGEs cross-link collagen fibers within the extracellular matrix. While normal collagen cross-linking is necessary for bone strength, the excessive, non-enzymatic cross-links induced by AGEs make the collagen more brittle and less able to absorb energy. This reduces bone toughness, meaning that less force is required to cause a fracture. Additionally, AGEs bind to their receptor (RAGE) on osteoblasts and osteoclasts, triggering inflammatory signaling that further disrupts normal bone turnover. Studies have shown that elevated serum AGE levels correlate with increased fracture risk independent of bone mineral density (BMD).

Imbalance in Bone Remodeling

Bone is a dynamic tissue that undergoes continuous remodeling orchestrated by osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). Diabetes disrupts this delicate balance. In Type 1 diabetes, the absence of insulin — a hormone with anabolic effects on bone — reduces osteoblast activity and bone formation. In Type 2 diabetes, insulin resistance and compensatory hyperinsulinemia initially stimulate osteoblast proliferation, but over time, the bone cells become less responsive. Furthermore, hyperglycemia itself can inhibit osteoblast differentiation and promote apoptosis. At the same time, osteoclast activity may be increased due to inflammatory cytokines such as TNF‑α and IL‑6, which are elevated in diabetes. The net effect is a state of low bone formation and high bone resorption, leading to microarchitectural deterioration. Trabecular bone (the spongy interior of vertebrae and the ends of long bones) is particularly affected, with thinner, more widely spaced trabeculae.

Hormonal and Inflammatory Factors

Diabetes also alters several hormones and signaling molecules that regulate bone metabolism. In Type 2 diabetes, hyperinsulinemia can downregulate insulin-like growth factor 1 (IGF‑1) signaling in bone, impairing osteoblast function. Amylin, a hormone co-secreted with insulin, normally suppresses osteoclast activity, but its deficiency in Type 1 diabetes contributes to increased bone resorption. Adipokines such as leptin and adiponectin, which are dysregulated in obesity-related Type 2 diabetes, also modulate bone cell activity. In addition, chronic low-grade inflammation characteristic of diabetes raises levels of pro‑inflammatory cytokines that promote osteoclastogenesis and inhibit bone formation. These hormonal and inflammatory changes compound the direct effects of hyperglycemia, creating a hostile environment for skeletal health.

Type 1 vs. Type 2 Diabetes – Different Risks, Similar Consequences

While both major types of diabetes increase fracture risk, the underlying mechanisms and bone phenotypes differ. In Type 1 diabetes, the onset is typically during childhood or adolescence, a critical period for bone mass accrual. Insulin deficiency reduces bone formation during growth, resulting in lower peak bone mass. Many individuals with Type 1 diabetes also have reduced bone turnover markers and lower BMD Z‑scores compared to age‑matched controls. Fracture risk is increased approximately 1.5‑ to 3‑fold, with the hip being the most commonly affected site.

Type 2 diabetes presents a paradox. BMD is often normal or even higher than in individuals without diabetes, which might suggest protection from fractures. Yet epidemiological studies consistently show a higher fracture risk, particularly at the hip and proximal humerus. This discrepancy is explained by poor bone quality — the bone is denser but more brittle due to AGE accumulation, abnormal microarchitecture, and impaired microdamage repair. The “bone quality” concept is critical: bone strength depends not only on how much bone is present but also on its material properties, architecture, and turnover. In Type 2 diabetes, the bone may appear robust on DXA scans, but it is weaker than expected for its density. The risk of falls is also elevated due to peripheral neuropathy, retinopathy, and hypoglycemic episodes, further increasing fracture incidence.

Fracture Risk in Individuals with Diabetes

Fractures in people with diabetes are not only more common but also more difficult to treat. The increased risk affects multiple skeletal sites, and complications such as delayed healing, infection, and implant failure are more frequent. Understanding the magnitude and patterns of this risk is essential for clinicians.

Fracture Sites and Prevalence

The hip is the most thoroughly studied fracture site in diabetes. Meta‑analyses report a relative risk (RR) of hip fracture of approximately 1.3 to 1.6 for Type 2 diabetes and 3 to 6 for Type 1 diabetes. Vertebral fractures are also common; even though they may not always present acutely, they contribute to chronic back pain, height loss, and kyphosis. Wrist and humeral fractures are elevated, especially in older women with Type 2 diabetes. Foot and ankle fractures deserve special attention because diabetic neuropathy can mask pain, leading to delayed diagnosis and Charcot neuroarthropathy. The overall burden is substantial: one large cohort study found that the excess fracture risk in Type 2 diabetes was equivalent to aging about 10 years in terms of hip fracture probability.

Beyond Bone Density: Why Quality Matters

Standard clinical practice uses dual‑energy X‑ray absorptiometry (DXA) to diagnose osteoporosis and assess fracture risk. However, DXA measures areolar bone mineral density (g/cm²), which does not capture the material or structural deterioration in diabetic bone. Consequently, many individuals with diabetes who fracture have T‑scores that are not in the osteoporotic range. Fracture risk assessment tools such as FRAX® do not currently include diabetes as an independent risk factor, meaning they may underestimate fracture probability in this population. Researchers are exploring complementary imaging techniques, such as trabecular bone score (TBS), high‑resolution peripheral quantitative computed tomography (HR‑pQCT), and micro‑finite element analysis, to better evaluate bone quality in diabetes. TBS, in particular, has shown promise in discriminating fracture status in Type 2 diabetes independently of BMD.

Medications and Bone Health in Diabetes

Certain glucose‑lowering medications also influence bone metabolism, and their effects must be considered when managing a patient with diabetes and high fracture risk. The choice of therapy can either protect or harm the skeleton.

Thiazolidinediones (TZDs)

Thiazolidinediones, such as rosiglitazone and pioglitazone, are insulin sensitizers that activate PPAR‑γ. While effective for glycemic control, TZDs increase bone loss and fracture risk, particularly in women. PPAR‑γ activation promotes differentiation of mesenchymal stem cells into adipocytes rather than osteoblasts, reducing bone formation. TZDs also increase osteoclast activity. The Food and Drug Administration (FDA) issued a warning about increased fracture risk with TZD use. These agents should be avoided or used with caution in older adults, especially women with additional risk factors for osteoporosis.

SGLT‑2 Inhibitors

Canagliflozin and other SGLT‑2 inhibitors lower blood glucose by promoting glycosuria. Initial clinical trials reported an increased risk of lower limb amputations and fractures with canagliflozin, though subsequent analyses have yielded mixed results. The fracture risk appears modest and may be related to volume depletion and falls rather than a direct effect on bone. However, SGLT‑2 inhibitors cause phosphate excretion, which can stimulate parathyroid hormone (PTH) and potentially increase bone turnover. Current evidence suggests that the fracture risk is low overall, but caution is warranted in patients with chronic kidney disease or pre‑existing bone disease.

Insulin

Insulin therapy, while essential for Type 1 diabetes and many cases of advanced Type 2 diabetes, carries a risk of hypoglycemia that can lead to falls. Additionally, chronic hyperinsulinemia may downregulate the IGF‑1 axis in bone. Nevertheless, insulin has anabolic effects on bone at physiological levels, and its net effect on fracture risk is likely neutral when hypoglycemic episodes are minimized.

Metformin, sulfonylureas, and newer agents like GLP‑1 receptor agonists and DPP‑4 inhibitors appear to have neutral or even beneficial skeletal effects in most studies. GLP‑1 receptor agonists may reduce fracture risk through effects on bone turnover and body weight. Clinicians should individualize diabetes pharmacotherapy based on a patient’s fracture risk profile.

Prevention and Management Strategies

Given the high burden of fractures in diabetes, proactive measures are needed to preserve bone health. A multifaceted approach combining glycemic control, nutrition, exercise, fall prevention, and adequate monitoring can significantly reduce risk.

Blood Glucose Control

Optimal glycemic control is the cornerstone of preventing diabetes‑related bone complications. Lowering HbA1c reduces the formation of AGEs, thereby preserving collagen integrity. Intensive insulin therapy in Type 1 diabetes has been shown to improve bone formation markers. However, aggressive glucose lowering must be balanced against the risk of hypoglycemia, which increases fall risk. Individualized targets that minimize both hyperglycemia and hypoglycemia are essential. Avoiding large glycemic swings may be particularly important for bone health.

Nutrition: Calcium, Vitamin D, and Protein

Individuals with diabetes often have suboptimal intake of bone‑essential nutrients. Calcium and vitamin D are critical for bone mineralization and muscle function. The National Institutes of Health (NIH) recommends 1000‑1200 mg of calcium daily (from diet and supplements if needed) and 600‑800 IU of vitamin D, though higher doses may be necessary for those with deficiency. Vitamin D levels should be monitored and supplemented as needed, especially because diabetes is associated with lower 25‑hydroxyvitamin D concentrations. Adequate protein intake is also important for maintaining muscle mass and bone matrix. Some evidence suggests that Mediterranean or plant‑based diets rich in fruits, vegetables, and whole grains may reduce AGE levels and improve bone health. Magnesium, vitamin K, and potassium also play roles in bone metabolism and should be obtained through a balanced diet.

Exercise Recommendations

Physical activity is a powerful intervention for improving bone density, muscle strength, and balance. Weight‑bearing exercises (walking, jogging, stair climbing) and resistance training (lifting weights, resistance bands) stimulate bone formation and increase BMD at sites most prone to fracture. For individuals with diabetes, exercise also improves glycemic control and reduces fall risk. The American Diabetes Association (ADA) recommends at least 150 minutes of moderate‑to‑vigorous aerobic activity per week, along with two to three sessions of resistance training. Tailored programs that address individual comorbidities — such as peripheral neuropathy or diabetic foot ulcers — ensure safety while maximizing benefits.

Fall Prevention

Falls are a major contributor to fractures in people with diabetes. Peripheral neuropathy causes loss of sensation and proprioception in the feet, increasing unsteadiness. Visual impairment from retinopathy or cataracts further compromises balance. Hypoglycemia can cause dizziness or syncope. Comprehensive fall risk assessment should include review of medications (especially those causing sedation or orthostatic hypotension), vision checks, and home safety evaluations. Interventions such as balance training (Tai Chi), muscle‑strengthening exercises, and use of assistive devices can reduce falls. Managing neuropathic pain and providing appropriate footwear also help.

Bone Density Monitoring

Because diabetic bone disease can exist with normal DXA results, the decision to screen should not rely solely on BMD T‑scores. Many guidelines recommend earlier and more frequent bone density testing in individuals with long‑standing diabetes, especially postmenopausal women and men over 50. The trabecular bone score (TBS), when available, can provide additional information about bone microarchitecture. In high‑risk individuals, bone turnover markers may be measured to assess remodeling status. When osteoporosis is diagnosed (or if a fragility fracture occurs), treatment with antiresorptive or anabolic agents such as bisphosphonates, denosumab, teriparatide, or romosozumab should be considered. These medications have been shown to reduce fracture risk in the general population, though specific data in diabetes patients are less robust. The decision to treat should incorporate fracture risk, renal function, and potential interactions with diabetes medications.

The Role of Healthcare Providers

Bone health should be an integral component of comprehensive diabetes care. Primary care physicians, endocrinologists, and geriatricians must be aware of the increased fracture risk and actively assess for it. This means asking about falls, back pain, and prior fractures; performing a “get‑up‑and‑go” test for mobility; and checking for kyphosis or height loss. Laboratory evaluation should include vitamin D and calcium status, and when indicated, bone turnover markers. Referral to a bone health specialist or a fracture liaison service can help ensure appropriate workup and treatment. Patient education is equally important: individuals with diabetes should understand that their disease affects not only blood sugar but also their bones, and that proactive steps — good control, proper nutrition, exercise, and fall prevention — can preserve their skeletal strength.

Conclusion

The impact of diabetes on bone health is profound and multifaceted. From the accumulation of AGEs that embrittle collagen to the disruption of normal bone remodeling and the added risks of falls from neuropathy, diabetes creates a perfect storm for fractures. The paradox of Type 2 diabetes — higher BMD yet higher fracture risk — underscores the importance of bone quality over quantity. Clinical management must go beyond glycemic control to include systematic fracture risk assessment, tailored pharmacotherapy, and lifestyle interventions that strengthen the skeleton and reduce falls. By integrating bone health into routine diabetes care, clinicians can help their patients avoid the devastating consequences of fractures and maintain an active, independent life for years to come.

For further reading, see the National Library of Medicine review on diabetes and bone, the ADA position statement on diabetes and bone health, and the Bone and Joint Initiative report.